Capital Invest - Medical Consulting 

Today, capital investors are facing increasing challenges when it comes to combination of risk reduction with return of investment. Due to the fact that classical/conservative investments are often not associated with a high margin of ROI, biotechnology is gaining increasing popularity. However, investments in biotechnology are considered by most institutional investors to constitute high-risk investments unless these investors do have experts in biotechnology analysing the portfolio, risks and chances of the respective candidate companies. 

Dr. Jürs offers personalized and tailored medical-scientific analysis packages for each investor, so please be so kind to contact Dr. Jürs directly to discuss suitable packages for you.